The Oncologist · 12 Nov 2026
Patient-reported outcomes from ASCENT-03: sacituzumab govitecan vs chemotherapy in advanced triple-negative breast cancer
Kevin Punie, Sara M Tolaney, Sara A Hurvitz, Carlos Barrios, Andreas Schneeweiss, Joohyuk Sohn, Eriko Tokunaga, Adam Brufsky, Yeon Hee Park, Binghe Xu, Roberto Hegg, Mafalda Oliveira, Alessandra Fabi, Yuanhui Zhang, Hao Wang, Yutian Mu, Rosemary Delaney, Javier Cortés
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Abstract Background In the ASCENT-03 study, first-line sacituzumab govitecan (SG) led to a statistically significant progression-free survival improvement vs chemotherapy in participants with metastatic triple-negative breast cancer (mTNBC) who were not candidates for PD-(L)1 inhibitors. We report patient-reported outcomes from ASCENT-03. Methods 558 participants were randomized 1:1 to SG or chemotherapy. Participants completed the EORTC QLQ-C30, EORTC QLQ-BR23, EQ-5D-5L, and FACT-GP5 questionnaires. Key secondary endpoints were change from baseline (CFB) at week 25 in physical functioning and time-to-first-meaningful deterioration (TTD) in fatigue. Additional exploratory analyses were performed for other EORTC QLQ-C30 domains and other questionnaires. Results Least-squares mean CFB at week 25 favored SG for physical functioning (difference, 6.89; 95% CI, 3.50-10.28); TTD in fatigue was similar between treatment groups (hazard ratio, 0.98; 95% CI, 0.80-1.19). Least-squares mean CFB also favored SG for role functioning, global health status/quality of life (QOL), fatigue, pain, and dyspnea and favored chemotherapy for diarrhea. TTD favored SG for dyspnea and chemotherapy for nausea/vomiting and diarrhea. Time-to-first-meaningful improvement favored SG for physical, role, cognitive, and social functioning; fatigue; insomnia; appetite loss; and constipation. Other patient-reported outcomes consistently favored SG. Conclusions SG provided meaningful and sustained benefits in QOL vs chemotherapy. Although SG is associated with known increased gastrointestinal side effects, they can be managed and did not adversely affect functioning, long-term QOL, or treatment tolerability. These data complement previous efficacy results and support first-line SG as a new standard of care for patients with mTNBC who are not candidates for PD-(L)1 inhibitors. (ClinicalTrials.gov number, NCT05382299)
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.